Interim FDGPET/CT for predicting the outcome in patients with head and neck cancer

Chen, Shang-Wen; Hsieh, T’sang‐T’ang; Yen, Kuo‐Yang; Yang, Shih Neng; Wang, Yao Ching; Chien, Chun Ru; Liang, Ji An; Kao, Chia Hung

doi:10.1002/lary.24826

Cited by 40 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thanks to its ease of use, it was historically the first parameter analyzed. SUVmax was correlated with overall-or disease free survival in 11 studies (Allal et al, 2002;Brun et al, 2002;Castaldi et al, 2012;Chen et al, 2014;Farrag et al, 2010;Higgins et al, 2012;Kitagawa et al, 2003;Machtay et al, 2009;Matoba et al, 2015;Rasmussen et al, 2015;Sanghera et al, 2005). SUVmax allows to identify patients with a high risk of events (death or recurrence).…”

Section: Suvmax and Metabolic Tumor Volumementioning

confidence: 99%

“…Seven studies (374 patients) evaluated the predictive value of PET performed during RT ± CT (Brun et al, 2002;Castaldi et al, 2012;Chen et al, 2014;Farrag et al, 2010;Hentschel et al, 2011;Min et al, 2016Min et al, , 2015. All but one of them found a correlation between PET parameters RT ± CT and clinical outcome.…”

Section: Predictive Value Of Quantitative Pet Parameters During Chemomentioning

confidence: 99%

See 1 more Smart Citation

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Castelli

Bari

Depeursinge

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

International audience18 F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) allows to quantify the metabolic activity of a tumor (glycolysis) and has become a reference tool in oncology for the staging, restaging, radiotherapy planning and monitoring response in many cancers. Quantitative analyses have been introduced in order to overcome some of the limits of the visual methods, allowing an easier and more objective comparison of the inter- and intra-patients variations. The aims of this review were to report available evidences on the clinical value of quantitative PET/CT parameters in HNC. Forty-five studies, for a total of 2928 patients, were analyzed. Most of the data available dealt with the intensity of the metabolism, calculated from the Standard Uptake Value (SUV). Metabolic Tumor Volume (MTV) was well correlated with overall survival and disease free survival, with a higher predictive value than the maximum SUV. Spatial distribution of metabolism and textural analyses seems promising

show abstract

Section: Suvmax and Metabolic Tumor Volumementioning

confidence: 99%

Section: Predictive Value Of Quantitative Pet Parameters During Chemomentioning

confidence: 99%

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Castelli

Bari

Depeursinge

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…P ET/CT is critical to the management of patients with head and neck squamous cell carcinoma (HNSCC), given its high accuracy in pretreatment staging and the detection of persistent and recurrent disease after therapy compared with CT or MR imaging, allowing salvage treatment to be initiated in a timely manner. [1][2][3][4][5][6][7][8][9][10][11][12] The high negative predictive value (NPV) of posttreatment PET/CT in patients with a complete response has been established. 10 It was demonstrated in a prospective, randomized controlled trial that concluded that planned neck dissection can be deferred in patients with HNSCC with a complete response on initial posttreatment PET/CT following definitive chemoradiation therapy.…”

mentioning

confidence: 99%

Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Wangaryattawanich

Branstetter

Hughes

et al. 2018

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

In patients with an incomplete response after treatment of head and neck squamous cell carcinoma, the negative predictive value of the first posttreatment FDG-PET/CT was 85%, which is lower than the 91% negative predictive value of FDG-PET/CT in patients with an initial complete response. Patients with an incomplete response (NI-RADS 2) should undergo more frequent clinical and imaging surveillance than patients with an initial complete response (NI-RADS 1).

show abstract

“…One of these studies used metabolic rate derived from plasma FDG level of PET however routine calculation of metabolic rate in clinical practice is not practical for most centres. All, but two studies, included nasopharyngeal cancer and the primary treatment modalities in four studies were heterogeneous, using RT or CRT. Two studies did not confirm the predictive value of mid‐treatment FDG‐PET scans …”

Section: Resultsmentioning

confidence: 99%

“…However, our group reported the absolute values rather than the percentage reduction in metabolic parameters were more predictive of LRFS and DFS but not OS, while TLG was found to be a better predictor than SUV max or MTV. 66 Of seven studies in this group, [67][68][69][70][71][72] only one study 66 reviewed MTV and TLG as predictive indicators of therapeutic response. One of these studies used metabolic rate derived from plasma FDG level of PET 70 however routine calculation of metabolic rate in clinical practice is not practical for most centres.…”

Section: Choice Of Primary Treatmentmentioning

confidence: 99%

A review of the predictive role of functional imaging in patients with mucosal primary head and neck cancer treated with radiation therapy

et al. 2016

View full text Add to dashboard Cite

Advanced radiotherapy techniques, such as intensity-modulated radiotherapy, have been reported to reduce toxicities by improving the dose conformity in mucosal primary head and neck cancer (MPHNC). However, to further optimize the therapeutic ratio, details on individual patient and disease characteristics may be necessary to tailor treatments. This is likely to include identifying poor responders for treatment intensification and good responders for de-escalation strategies. Non-invasive, repeatable imaging biomarkers are attractive modalities in both pre-treatment and intra-treatment response prediction with a view to individualized treatment options. This review has assessed the current literature on the prognostic/predictive role of widely available functional imaging (FI) studies such as fMRI(functional magnetic resonance imaging), functional computed tomography (fCT) and positron-emission-tomography(PET). A literature search was carried out using Medline, Embase and PubMed. Studies were included if imaging was undertaken pre and/or during radiotherapy (with or without the addition of chemotherapy and/or surgery). A total of 99 relevant studies were identified: 14 fMRI, 10 fCT, 59 FDG-PET and 16 non-FDG-PET studies. These articles were reviewed to identify imaging parameters demonstrating a correlation with patient outcome or a factor considered to impact on patient outcome and thus likely to be of potential predictive value in MPHNC and associated future radiotherapy treatment directions. Several studies have demonstrated that both pre-treatment and mid-treatment FDG-PET is predictive of outcomes. However, further studies are required to confirm the role of other imaging studies including fMRI and PET using other tracers. There is large heterogeneity within and between published studies, including tumour sites, treatment options, outcome endpoints and parameters assessed. We propose a minimum set of factors that should be reported and make recommendations for studies evaluating the predictive utility in MPHNC.

show abstract

Interim FDGPET/CT for predicting the outcome in patients with head and neck cancer

Abstract: 4.

Cited by 40 publications

References 22 publications

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

A review of the predictive role of functional imaging in patients with mucosal primary head and neck cancer treated with radiation therapy

Contact Info

Product

Resources

About